Advertisement
UK markets close in 3 hours 40 minutes
  • FTSE 100

    7,858.24
    -107.29 (-1.35%)
     
  • FTSE 250

    19,428.48
    -270.41 (-1.37%)
     
  • AIM

    741.59
    -8.69 (-1.16%)
     
  • GBP/EUR

    1.1703
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2452
    +0.0006 (+0.05%)
     
  • Bitcoin GBP

    50,315.65
    -2,798.72 (-5.27%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     
  • DOW

    37,735.11
    -248.13 (-0.65%)
     
  • CRUDE OIL

    85.09
    -0.32 (-0.37%)
     
  • GOLD FUTURES

    2,389.60
    +6.60 (+0.28%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     
  • DAX

    17,838.73
    -187.85 (-1.04%)
     
  • CAC 40

    7,959.72
    -85.39 (-1.06%)
     

Enfusion (ENFN) to Report Q1 Earnings: What's in the Offing?

Enfusion ENFN is set to report first-quarter 2023 results on May 9.

For the quarter, the Zacks Consensus Estimate for revenues is currently pegged at $42.27 million, suggesting growth of 23.83% from the figure reported in the year-ago quarter.

The consensus mark for first-quarter bottom line has remained unchanged in the past 30 days. The Zacks Consensus Estimate for first-quarter earnings is pegged at 3 cents per share.

Enfusion, Inc. Price and EPS Surprise

Enfusion, Inc. Price and EPS Surprise
Enfusion, Inc. Price and EPS Surprise

Enfusion, Inc. price-eps-surprise | Enfusion, Inc. Quote

Factors to Note

Enfusion’s first-quarter results are expected to reflect benefits of healthy demand and solid execution. The top line is expected to have increased in the to-be-reported quarter.

The company continues to build meaningful commercial expansion within its existing client base. With 39 new clients in the previous quarter, the company reached a total of 819 clients. This trend is expected to have positively impacted the to-be-reported quarter.

In the first quarter, Enfusion partnered with leading risk management provider Qontigo. This partnership aims to deliver Aximo risk to Enfusion clients for preventing and complying with threats. This is expected to have benefited the top line in the to-be-reported quarter.

Enfusion is continuously improving its margin profile and focused on returning to its historical profitability. The company expects adjusted EBITDA for 2023 in the range of $32 million to $34 million.

What Our Model Says

Per the Zacks model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here.

ENFN currently has an Earnings ESP of -5.26% and a Zacks Rank #1. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Stocks to Consider

Here are some other stocks worth considering, as our model shows that these have the right combination of elements to beat on earnings this season.

Centerra Gold CGAU has an Earnings ESP of +192.31% and sports a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Centerra Gold is set to report its first-quarter fiscal 2023 results on May 15. The Zacks Consensus Estimate is pegged at a loss of 4 cents per share, suggesting a decrease of 121.05% from the prior-year period’s reported figure.

Bitfarms BITF has an Earnings ESP of +180.00% and a Zacks Rank #2 at present.

Bitfarms is scheduled to release its first-quarter 2023 results on May 15. The Zacks Consensus Estimate is pegged at a loss of 3 cents per share, suggesting a decline of 250% from the prior-year quarter’s reported figure.

Copa Holdings CPA has an Earnings ESP of +19.57% and carries Zacks Rank #2 at present.

Copa Holdings is scheduled to release its first-quarter 2023 results on May 10. The Zacks Consensus Estimate is pegged at $3.03 per share, suggesting an increase of 332.86% from the prior-year quarter’s reported figure.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

ADVERTISEMENT

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Copa Holdings, S.A. (CPA) : Free Stock Analysis Report

Centerra Gold Inc. (CGAU) : Free Stock Analysis Report

Bitfarms Ltd. (BITF) : Free Stock Analysis Report

Enfusion, Inc. (ENFN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research